MedTrace Logo

AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy

NCT07263204 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 15000

Last updated 2025-12-04

No results posted yet for this study

Summary

By harnessing artificial intelligence to decode the 12-lead electrocardiogram, the project will enable precise ECG-based phenotyping of hypertrophic cardiomyopathy-accurately classifying septal, apical, and other morphologic subtypes-while simultaneously differentiating HCM from hypertensive heart disease, aortic stenosis, and other phenocopy disorders.

Conditions

  • Hypertrophic Cardiomyopathy (HCM)
  • Left Ventricular Hypertrophy

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2026-06-01
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07263204 on ClinicalTrials.gov